Floatz logo

Seroquel®

Generalized Anxiety Disorder

Icahn School of Medicine at Mount SinaiPhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Generalized Anxiety Disorder cohort.

Asset / SponsorPhaseRating
Risperdal
University of South Florida
Phase 4BB
ZIPRASIDONE
VA Palo Alto Health Care System
Phase 4BB
Valproic Acid
University of South Florida
Phase 4BB
Acamprosate
Medical University of South Carolina
Phase 4BB
Paroxetine
Beijing Tongren Hospital
Phase 1CC
Isoproterenol
Laureate Institute for Brain Research, Inc.
N/AD
Duloxetine
D
Abbv-932
AbbVie
Phase 1NR

Same molecule, other indications

Seroquel® is also rated in:

substance abuseDormant
BBB
Indicative ·
78 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →
mood disorderDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →